We report here two new cases of glucose phosphate isomerase (GPI) deficiency associated with hemolytic anemia and present the results of molecular analysis of the five Japanese GP1 variants. A Japanese girl (GP1 Fukuoka) had an episode of prolonged neonatal jaundice and at 3 years of age was admitted due t o acute hemolytic crisis occurring with upper respiratory tract infection. Red blood cell (RBC) GP1 activity was decreased t o 11.8% of normal and the reduced glutathione (GSH) level of RBCs was slightly decreased. A !%year-old Japanese man (GP1 Iwate) was hospitalized due t o chronic active hepatitis, and compensated hemolysis was noted. RBC GP1 activity of the proband was decreased t o 18.896, and the GSH content was about half of the normal mean value. Sequencing of the reticulocyte GPlcDNA showed homozygous missense mutations 1028CAG -+ COG (343GIn -+ Argl, 14ACC -+ A7C (5Thr -t Ile), 671ACG -+ ATG (224Thr -+ Met), and 1615GAC + AAC LUCOSE PHOSPHATE isomerase (D-glucose-6-phosphate keto1 isomerase, EC 5.3.1.9; GPI) catalyzes interconversion of glucose-6-phosphate and fructose 6-phosphate in the Embden-Meyerhof glycolytic pathway. GP1 is an essential enzyme for carbohydrate metabolism in all tissues, and null expression of the murine GP1 gene has been found to be embryonic lethal.'.' In humans, the GP1 gene locus is located on chromosome 19,' and the gene spans more than 40 kb, including 18 exons and 17 introns!" Human GP1 has been purified from several tissues such as muscle, erythrocytes, and the pla~enta,'"~ and no tissue-specific isozymes have been reported. However, in several species and tissues, including human placenta, various GP1 isoforms presumably modified at the posttranslational level have been identified.""' Neuroleukin (NLK), a protein that acts as both a neurotrophic factor and a lymphokine, has been isolated from mouse salivary glandsI4; subsequently, the primary structure of NLK was found to be identical to GP1 by comparison of the cDNA sequence^.'^,'^ The cDNA sequence encodes 558 amino acid residues. The enzyme consists of two identical subunits with the molecular weight of approximately 63,000, whereas NLK is active as a monomer. The crystal structure of porcine GP1 has been elucidated at 2.6-A resolution."
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Hereditary hemolytic anemia associated with GP1 deficiency was first reported in 1968." Since then, more than 40 families have been reported, making this the third most common red blood cell (RBC) enzymopathy after glucose-6-phosphate dehydrogenase (G6PD) and pyruvate kinase (PK) d e f i c i e n~y . '~-~~ Frequency of heterozygosity was estimated as 2.3 in 1,000 subjects in the Japanese population." In the most severe case, GP1 deficiency caused hydrops fetali~.'~ Enzymatic characterization has shown that most GP1 variants were unstable, but enzyme kinetics were not necessarily impaired." These observations make it quite difficult to distinguish each variant by biochemical analysis. Thus, to investigate the genetic background of GP1 deficiency, analysis at the DNA level might be essential. Eight GPI-deficient families have been reported to date by our g r o u~,~ and two newly (539Asp -+ Asn) in GP1 Narita, GP1 Matsumoto, GP1 Iwate, and GP1 Fukuoka, respectively. We also identified GP1 Kinki as a compound heterozygote of 1124ACA -* AGA(375Thr -+ Arg)/l615GAC -+ AAC(539Asp -+ Am). Our findings, together with the previous results of other investigators, showed that the GP1 gene mutations SO far identified were heterogeneous, although most GP1 variants had common biochemical characteristics such a0 heat instability and normal kinetics. Several amino acid substitutions were identified in the proximity of the catalytically important amino acid residues such as SerIAsp 1591160. Asp341, and Lyr518, which have been identified in the structurd analysis of the pig GPI. The molecular characterization of human GP1 variants, therefore, may provide new insights into the genotype-phenotype correlation of GP1 deficiency as well as the structure-function relationship of this enzyme. 0 1996 by The American Society of Hematology.
discovered Japanese families with GP1 deficiency, GP1 Fukuoka and GP1 Iwate, are presented in this report. We also describe here the molecular abnormalities identified in the five GP1 variants, including the new cases.
CASE REPORTS
A 3-year-old girl (GP1 Fukuoka) with an episode of prolonged neonatal jaundice was admitted to the Kyushu University Hospital due to acute hemolysis occumng with upper respiratory tract infection. Laboratory data at admission were as follows: hemoglobin (Hb) level, 6.9 gll00 m L ; reticulocyte level, 12.1%; RBC morphology, polychromasia; serum lactate dehydrogenase (LDH), 1,056 IU; total bilirubin, 3.5 mg/100 mL; direct bilirubin, 0.7 mg/lOO mL; indirect bilirubin, 2.8 mg/mL,. There was no consanguinity in her family. In the chronic phase, the Hb value recovered to 11.2 dl00 mL with persistent reticulocytosis (9.8%) and hyperbilirubinemia (total bilirubin, 4.0 mg/100 mL; direct and indirect bilirubin, 0.4 and 3.6 mgl 100 mL, respectively). A 54-year-old Japanese man (GP1 Iwate) was hospitalized to receive interferon therapy for chronic active hepatitis as a result of hepatitis C virus infection. Routine laboratory tests showed chronic hemolysis of unknown etiology. Laboratory data at admission were as follows: Hb level, 11.2 g100 mL; reticulocyte level, 10.6%; serum LDH, 326 IU; total bilirubin, 2.5 mg/100 mL; direct bilirubin, 0.8 mg/100 m L ; indirect, 1.7 mg/100 mL. Study of the family history showed that the grandparents of the proband were first cousins.
Clinical history, hematologic data, and enzymatic characteristics of GP1 Na~ita?~.'' GP1 Matsumoto,n.28 and GP1 KinkiZ9 have been reported previously.
MATERIALS AND METHODS
Restriction endonucleases were purchased from Takara Shuzo (Kyoto, Japan) and New England Biolabs (Beverly, MA). Avian myeloblastosis virus reverse transcriptase (AMVRT) was obtained from Seikagaku Kogyo (Tokyo, Japan). Taq DNA polymerase (AmpliTaq) was obtained from Perkin Elmer Cetus (Norwalk, CT). For the long polymerase chain reaction (PCR) experiment, a commercial kit (LAPCR kit version 2) from Takara Shuzo was used. NuSieve GTG agarose and SeaKem HGT agarose were obtained from FMC Bioproducts (Rockland, ME). DNA was sequenced using a DNA sequencing system (Model 373A; Applied Biosystems, Foster City, CA). The computer software DNASIS (Hitachi Software Engineering, Yokohama, Japan) was used to analyze nucleotide and amino acid sequences.
RBC enzyme activities and glycolytic intermediates were measured by protocols standardized previously by the International Committee for Standardization in HaematologyM or methods described by Minakami et aL3' Cellulose-treated RBCs" were homogenized in 4 v01 of 4 m o m guanidinium isothiocyanate solution containing 25 mmoVL sodium acetate (pH 6.0) and 0.12 mollL 0-mercaptoethanol, and reticulocyte RNA was purified by density gradient ultracentrifugation on a 5. 7 m o a cesium chloride c~shion.'~ Genomic DNA was purified from white blood cells by the standard proteinase K-sodium dodecyl sulfate method."
The oligonucleotides used in this study are listed in Table 1 . Two micrograms of human reticulocyte total RNA was reverse transcribed in a 20 pL mixture of SO mmollL Tris/HCI (pH 8.3), 40 mmoVL KCI, 8 mmoVL MgCI2, 0.5 mmoUL dNTP with 10 pmol of GPI-I primer, 100 U of ribonuclease inhibitor (Takara Shuzo), and 20 U of AMVRT. The reaction mixture was incubated at 42°C for 120 minutes, and then AMVRT was inactivated by heating at 95°C for 10 minutes. Aliquots of 1/10 of the cDNA mixture were then subjected to PCR amplification in a 50 pL mixture of 1 X LAPCR buffer (included in the kit), 0.4 mmol/L W T P with 10 pmol each of primers GPI-2 and GPI-7, and 2.5 U of LATaq DNA polymerase. The reaction mixture was subjected to 30 cycles of amplification at 94°C for 20 seconds, 60°C for 30 seconds, and 72°C for 210 seconds in GeneAmp PCR System 9600 (Perkin Elmer Cetus). The amplified cDNA spanned 1,736 bp covering the entire coding sequence and parts of the 5'-and 3'-untranslated regions were subsequently subcloned into the pCR I1 vector by TA cloning kit (InVitrogen, San Diego, CA). Clones were sequenced by the dideoxy chain termination method with fluorescent dideoxynucleotide (Dye Terminator Cycle Sequencing Kit; Perkin Elmer) and the primers GPI-2, -3, -4, -5, -6, -7, -8, -9, -11, and -12.
To confirm nucleotide changes detected in the cDNA, 0.5 pg of genomic DNA was amplified by PCR in a 50 pL mixture of 10 mmol/L Tris/HCI (pH 8.3). 50 mmoVL KCI, 1.5 mmoW MgClz, 0.001% gelatin, 0.2 mmol/L dNTP with 25 pmol of each primer listed in Table 2 , and 1.25 U of AmpliTaq DNA polymerase. The reaction mixture was subjected to 30 cycles of amplification at 94°C for 20 seconds, 60°C for I O seconds, and 72°C for 10 seconds in a GeneAmp PCR System 9600. The amplified DNA was digested with the restriction endonucleases listed in Table 2 to verify the nucleotide changes found in the cDNA.
RESULTS
RBC enzyme analysis showed that GP1 activity in GP1 Fukuoka was 6.4 IU/g Hb (1 1.8% of normal mean value) and the reduced glutathione (GSH) level of the proband's RBCs was slightly decreased to 47.8 mg/lOO mL RBC (74.9% of normal mean value). GP1 activity of her mother was 27.6 IU/g Hb, 51.0% of the normal mean value, suggesting heterozygosity for the mutant GP1 gene. The RBC GP1 activity in GP1 Iwate was decreased to 10.2 IU/g Hb (1 8.8% of normal mean value), and GSH content was 50.9% of normal mean value. GP1 Iwate showed a decreased level of fructose-6-phosphate (F6P; 2.4 nmoYmL RBC; range, 4.9 to 10.1 nmoYmL RBC [mean t SDI). In turn, the levels of fructose-l,6-diphosphate (F'DP; 9.8 nmoYmL RBC; range, 1.9 to 5.5 nmoVmL RBC [mean t SDI), glyceraldehyde-3-phosphate (GA3P; 8.7 nmoYmL RBC; range, 0 to 5.1 nmol/ mL RBC [mean 5 SDI), and nicotinamide adenine dinucleotide (NAD; 93.9 nmoVmL RBC; range, 50.0 to 68.2 nmoV mL RBC [mean -+ SDI) were increased relative to normal mean values. The ATP level was within normal limits (1, 192 nmoYmL RBC).
The human reticulocyte GPIcDNA sequences of the reticulocyte-rich control subject and from all of the GP1 variants examined showed a sequence discrepancy at nucleotide no. 603 CCC instead of CCG, which was deposited in GenBank (accession no. KO35 15) . Because previous ~tudies'*~.~'.~~ have not described this variation, we verified our results by genomic sequencing further 10 normal Japanese subjects and found that all had 603C. These results suggested that it might be a common DNA polymorphism in the Japanese population or a sequencing error. Xu and Beutle86 previously reported two DNA polymorphisms in this gene; however, none of these has been detected in Japanese GP1 variants.
GP1 Narita had a homozygous mutation at no. 1028 CAG to CGG (1028G, 343 Gln to Arg). This mutation replaced a neutral with a basic amino acid compatible with the faster migration rate of this variant towards the cathode on the starch gel electrophoresis described p r e v i o~s l y .~~ The substituted Gln is adjacent to the active site of the pig GPI, 341 Asp," suggesting that this mutation would affect the catalytic activity of GPI.
A homozygous missense mutation, 14 ACC to ATC (14T, 5 Thr to Ile), was identified in GP1 Matsumoto; this amino acid substitution changed the secondary structure of the amino-terminal region the GP1 monomer. This variant migrated as normal on electrophoresis and had the normal Michaelis constant for F6P, but was markedly heat labile. The Thr residue is phylogenetically conserved among mouse, pig, and human GPI, but not in yeast GPI'"'6.37 (Table 3 ).
The missense mutation 671ACG + ATG(671T, 224Thr * Met) has been identified in an allele of an African-American variant.36 Figure 1 summarizes GP1 activity, the degree of anemia, and the genotype data of the 671T mutation in the GP1 Iwate family, showing clearly that both the decreased GP1 activity and anemic phenotype were linked to the mutation. GP1 Fukuoka was found to be homozygous for the 1615GAC + AAC(1615A, 539Asp + Asn) mutation, whereas GP1 Kinki was heterozygous. Another missense mutation, 1124ACA + AGA(1124G, 375Thr + Arg), was observed in GP1 Kinki; this T375R mutation occurred at relatively conserved amino acid residues and caused an alteration in hydrophobicity.
DISCUSSION
Recent advances in the molecular analysis of the erythroenzymopathies showed that heterogeneous gene mutations caused aberrant enzyme function, leading to nonspherocytic hemolytic anemia. The human GPIcDNA sequence had been elucidated by cloning ne~roleukin,'~ and the genomic structure of the human GP1 gene has been clarified r e~e n t l y .~.~ Thus, it was possible for us to study the hemolytic anemia associated with GP1 deficiency at the molecular level. To date, 15 GP1 variants have been analyzed at the molecular level, and 13 missense mutations, 1 nonsense mutation, and 1 splice site mutation have been reported.
Because both the glycolysis and the pentose-phosphate shunt are indispensable for RBC metabolism, complete deficiency of the enzymes involved in those metabolic pathways may result in embryonic lethal effect, as previously shown in murine GP1 system.'.' The molecular characterization of GP1 variants showed that the gene defects were mostly point mutations that led to enzymatic instability. Homozygous state of null mutation of the enzymes governed by a single locus gene may be lethal. In contrast, in hemolytic anemia associated with deficiencies of other glycolytic enzymes such as PK and phosphofructokinase (PFK), null expression of genes for major isoforms in RBCs had been shown to be compensated by other isozyme genes. In severe PK deficiency, either persistence or reactivation of the fetal (M%-)type PK gene expression has been observed in homozygous PK variants'
For another example, the M(musc1e)-type PFK deficiency, the type VI1 glycogen storage disease, caused mild hemolytic anemia despite drastic homozygous mutations of the M-type gene,'"' because the L(1iver)-type PFK that was physiologically expressed in RBCs could compensate for the M-type PFK deficiency!' Study of the glycolytic intermediates of GP1 Iwate showed decreased F6P and elevated FDP levels in the proband's RBCs, whereas the G6P level was within the normal range.
Levels of F6P and FDP, metabolites distal to the step catalyzed by GPI, were reported to be decreased in most cases of GP1 defi~iency,~' although elevated FDP levels were identified in the RBCs of GP1 Narita and GP1 Matsumoto.26.28 The elevation of F6P, FDP, and GA3P levels might reflect acceleration of the pentose phosphate shunt that is activated by blockage of G6P isomerization.2J
Clinical profiles, hematologic data, RBC GP1 activity, and results of the molecular characterization of the variant GP1 genes are summarized in Table 3 . We identified 5 distinct missense mutations in this study, among which 671T(T224M) has been identified in an African-American variant.'6 Previously, we reported the homozygous missense mutations of GP1 Narita and GP1 Matsumoto,"' and the same mutation as that of GP1 Narita was reported in an Italian patient, GP1 M o~c o n e .~~ Single amino acid substitutions such as Q343R and D539N were identified near the putative active sites that have been delineated by structural studies of pig GPL3' These residues are phylogenetically well conserved, as shown in Table 4 . 343Gln corresponds to the 341Gln of pig GPI, adjacent to the reported active site residue 342 Asp. Thus, it is most likely that GP1 Narita, a variant GP1 with Q343R, may cause alterations in the kinetic characteristics of GPI, although enzymatic analysis did not show any changes in kinetics. To evaluate the altered enzymatic characteristics caused by each mutation, improvements in the purification and characterization of GP1 variants are required. Abbreviation: -no amino acid sequence homology.
Previous enzymatic characterization of the GP1 variants indicated that most GP1 variants were heat-labile but had normal kinetics,*' suggesting the homogenous genetic background of this disease compared with other erythroenzymopathies such as PK and G6PD deficiency. However, recent results of GP1 gene analysis disclosed fairly heterogeneous genetic abnormalities in this disease. Further studies are necessary to clarify the molecular pathology of GP1 deficiency and may also provide important information regarding the genotype-phenotype relationship of GPI-deficient hemolytic anemia. characterization 
